These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2147979)

  • 21. Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
    Prasad C; Spahn SA; Ikegami H
    Biochem Biophys Res Commun; 1989 Feb; 159(1):48-52. PubMed ID: 2522303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems.
    Sonsalla PK; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1986 Sep; 238(3):932-7. PubMed ID: 2943891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mechanism underlying neuroleptic induced oral dyskinesias in rats.
    Rosengarten H; Schweitzer JW; Friedhoff AJ
    Pol J Pharmacol; 1993; 45(4):391-8. PubMed ID: 7906991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
    [No Abstract]   [Full Text] [Related]  

  • 26. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
    Koller W; Curtin J; Fields J
    Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and experimental studies of phenytoin-induced hyperkinesias.
    Nausieda PA; Koller WC; Weiner WJ; Klawans HL
    J Neural Transm; 1979; 45(4):291-305. PubMed ID: 490152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.
    Marsden CD; Jenner P
    Psychol Med; 1980 Feb; 10(1):55-72. PubMed ID: 6104342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Abnormal movements induced by psychotropic drugs].
    Rondot P; Bathien N
    Encephale; 1979; 5(1):41-8. PubMed ID: 477589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
    Ben-Shachar D; Pinhassi B; Youdim MB
    Eur J Pharmacol; 1991 Sep; 202(2):177-83. PubMed ID: 1687031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states.
    LaHoste GJ; Wigal T; King BH; Schuck SEB; Crinella FM; Swanson JM
    Exp Clin Psychopharmacol; 2000 Feb; 8(1):125-132. PubMed ID: 10743913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
    Blin J; Baron JC; Cambon H; Bonnet AM; Dubois B; Loc'h C; Mazière B; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Nov; 52(11):1248-52. PubMed ID: 2574230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic dosage, duration, and tardive dyskinesia.
    Allen RE; Stimmel GL
    Dis Nerv Syst; 1977 May; 38(5):385-7. PubMed ID: 852370
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuroleptic classification: implications for tardive dyskinesia.
    Hyttel J; Christensen AV; Arnt J
    Mod Probl Pharmacopsychiatry; 1983; 21():49-64. PubMed ID: 6140632
    [No Abstract]   [Full Text] [Related]  

  • 37. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
    Yarbrough GG; Faison EP; Antolik EK
    Neurosci Lett; 1982 Dec; 34(3):321-3. PubMed ID: 6819493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiological mechanisms underlying tardive dyskinesia.
    Gerlach J
    Psychopharmacology Suppl; 1985; 2():98-103. PubMed ID: 2860666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.